康缘药业：金振口服液增加儿童流行性感冒适应症获得临床试验批准

Core Viewpoint - Kangyuan Pharmaceutical has received clinical trial approval for the new indication of its Jin Zhen oral solution for treating children's influenza, indicating potential market growth opportunities for the product [1] Group 1: Company Developments - Kangyuan Pharmaceutical announced the receipt of a clinical trial approval notice from the National Medical Products Administration for the Jin Zhen oral solution, which now includes a new indication for treating children's influenza (heat toxin attacking the lung syndrome) [1] - The Jin Zhen oral solution is a pediatric-specific traditional Chinese medicine that has been included in the national essential drug list and the national medical insurance catalog [1] Group 2: Market Potential - The product is expected to have a promising market outlook for the prevention and treatment of influenza in children [1]